FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294915483> ?p ?o ?g. }

• W4294915483 endingPage "368" @default.
• W4294915483 startingPage "363" @default.
• W4294915483 abstract "Free AccessObstructive Sleep ApneaSeverity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension Carolina C. Gonzaga, M.D., Krishna K. Gaddam, M.D., Mustafa I. Ahmed, M.D., Eduardo Pimenta, M.D., S. Justin Thomas, B.S., R.P.S.G.T., Susan M. Harding, M.D., Suzanne Oparil, M.D., Stacey S. Cofield, Ph.D., David A. Calhoun, M.D. Carolina C. Gonzaga, M.D. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author , Krishna K. Gaddam, M.D. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author , Mustafa I. Ahmed, M.D. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author , Eduardo Pimenta, M.D. Endocrine Hypertension Research Center and Clinical Center of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine, Princess Alexandra and Greenslopes Hospitals, Brisbane, QLD, Australia Search for more papers by this author , S. Justin Thomas, B.S., R.P.S.G.T. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author , Susan M. Harding, M.D. Sleep/Wake Disorders Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, AL Search for more papers by this author , Suzanne Oparil, M.D. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author , Stacey S. Cofield, Ph.D. Department of Biostatistics, University of Alabama at Birmingham, AL Search for more papers by this author , David A. Calhoun, M.D. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL Search for more papers by this author Published Online:August 15, 2010https://doi.org/10.5664/jcsm.27878Cited by:112SectionsAbstractPDF ShareShare onFacebookTwitterLinkedInRedditEmail ToolsAdd to favoritesDownload CitationsTrack Citations AboutABSTRACTBackground:We previously described a significant correlation between plasma aldosterone concentration (PAC) and severity of obstructive sleep apnea (OSA) in patients with resistant hypertension. This investigation examines the relationship between aldosterone status and OSA in patients with resistant hypertensive—with and without hyperaldosteronism.Methods and Results:One hundred and nine consecutive patients with resistant hypertension were prospectively evaluated with plasma renin activity (PRA), PAC, 24-hour urinary aldosterone excretion (UAldo), and polysomnography. Hyperaldosteronism (PRA < 1 ng·mL-1·h-1 and UAldo ≥ 12 μg/24-h) prevalence was 28% and OSA prevalence was 77%. In patients with hyperaldosteronism, OSA prevalence was 84%, compared with 74% in hypertensive patients with normal aldosterone levels. There were no significant differences in body mass index or neck circumference between aldosterone groups. PAC and UAldo were both significantly correlated with apnea-hypopnea index (AHI) in the high-aldosterone group (ρ = 0.568, p = 0.0009; ρ = 0.533, p = 0.002, respectively). UAldo correlated weakly with apnea-hypopnea index in the normal-aldosterone group, but there was no significant correlation between PAC and AHI in the normal-aldosterone group (ρ = 0.224, p = 0.049; ρ = 0.015, p = 0.898, respectively).Conclusions:Our analysis of patients with resistant hypertension confirms a markedly high prevalence of OSA in this group. Furthermore, severity of OSA was greater in those patients with hyperaldosteronism and related to the degree of aldosterone excess. The correlation between OSA severity and aldosterone supports the hypothesis that aldosterone excess contributes to greater severity of OSA.Citation:Gonzaga CC; Gaddam KK; Ahmed MI; Pimenta E; Thomas SJ; Harding SM; Oparil S; Cofield SS; Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010;6(4):363-368.INTRODUCTIONObstructive sleep apnea (OSA) and hypertension are both independently associated with increased cardiovascular risk.1–7 Furthermore, approximately 50% of patients with OSA have a diagnosis of hypertension, whereas 30% of hypertensive patients have OSA.8–11 Recently published evidence-based hypertension management guidelines identified OSA as an important identifiable cause of hypertension.12 The association of OSA and hypertension is particularly marked among patients with resistant hypertension, with studies reporting an OSA prevalence of 80% to 85% in these patients.13,14BRIEF SUMMARYCurrent Knowledge/Study Rationale: We previously described a significant correlation between plasma aldosterone concentration and severity of obstructive sleep apnea in patients with resistant hypertension. This investigation examines the relationship between aldosterone status and obstructive sleep apnea in patients with resistant hypertensive—with and without hyperaldosteronism.Study Impact: The positive relationship between hyperaldosteronism and severity of obstructive sleep apnea (OSA) observed in the current analysis supports the hypothesis that aldosterone excess contributes to the development of OSA. The results highlight the increased likelihood of hyperaldosteronism and OSA coexisting in patients with resistant hypertension and may explain, at least in part, the high prevalence of OSA in patients with resistant hypertension.Hyperaldosteronism is common in patients with resistant hypertension. Approximately 20% of patients with resistant hypertension have biochemical criteria consistent with primary aldosteronism.15–18 In patients with resistant hypertension in whom we had diagnosed hyperaldosteronism, we observed that many had been previously diagnosed with OSA. We, therefore, hypothesized that the 2 diseases may be mechanistically related, that is one contributing to the other. Our center noted increased aldosterone excretion in patients with resistant hypertension who had symptoms of OSA.19 We then showed that a significant correlation exists between plasma aldosterone concentration (PAC) and OSA severity in patients with resistant hypertension but not in normotensive control subjects.14 Although we cannot directly infer causality from these studies, these results are consistent with the hypothesis that aldosterone excess may contribute to worsening severity of OSA. To gain further insight into the association among resistant hypertension, OSA, and hyperaldosteronism, we evaluated the relationship between aldosterone levels and OSA severity in patients with resistant hypertension with and without hyperaldosteronism.METHODSStudy ParticipantsThe study was approved by the University of Alabama at Birmingham Institutional Review Board, and all subjects provided written informed consent prior to study participation. We prospectively enrolled 109 consecutive patients referred to the University of Alabama at Birmingham Hypertension Clinic for evaluation of resistant hypertension over a 6-year period (June 2002 to June 2008). The first 76 subjects of this current analysis were included in our prior evaluation relating OSA severity to PAC.14Resistant hypertension was defined as a blood pressure that remained above target values despite the concurrent use of 3 antihypertensive agents, prescribed at optimal dose amounts.12 All patients had been on a stable antihypertensive regimen for at least 4 weeks prior to evaluation. No antihypertensive medications were discontinued, except for spironolactone, eplerenone, amiloride, or triamterene, for which hydrochlorothiazide was substituted for at least 6 weeks prior to evaluation. Serum potassium levels were corrected as necessary with oral supplementation to maintain a serum level of greater than 3.5 mmol/L. Secondary causes of hypertension other than hyperaldosteronism, such as renovascular disease, pheochromocytoma, and Cushing syndrome, were excluded by laboratory analysis or suitable imaging, as clinically indicated. Patients with a history of recent myocardial infarction (within 6 months prior to study), congestive heart failure, chronic kidney disease (creatinine clearance [Cr Cl] < 60 mL/min per 1.73m2), or long-term corticosteroid therapy were excluded from enrollment.Blood Pressure MeasurementsSeated clinic blood pressure was measured manually using a mercury sphygmomanometer and an appropriate-sized cuff after 5 minutes of rest, according to standard guidelines. All patients underwent 24-hour ambulatory blood pressure monitoring (Spacelabs model 90207, Spacelabs Healthcare, Issaqhah, WA, or Suntech Medical model 0413, Morrisville, NC). The monitor recorded systolic and diastolic blood pressure every 20 minutes during the daytime (06:00 to 22:00) and every 30 minutes at night (22:00 to 06:00). The ambulatory data were included in the analysis if the monitoring period was at least 20 hours and there were no period of 2 hours or greater without measurements.Biochemical EvaluationAll subjects underwent biochemical evaluation in an ambulatory outpatient setting. Initial evaluation included an early morning (07:00-09:00) plasma renin activity (PRA) and PAC and a 24-hour urine collection for sodium (UNa), Cl Cr, and aldosterone (UAldo) on the subjects' ad-lib diet.Based on the biochemical results, patients were characterized according to aldosterone status. High-aldosterone status (H-Aldo) was defined as a suppressed PRA (< 1.0 ng·mL-1·h-1) and elevated UAldo (≥ 12 μg/24h). Normal-aldosterone status (N-Aldo) was defined as UAldo less than 12 μg/24h, the absence of suppressed PRA (≥ 1.0 ng·mL-1·h-1), or both. A cutoff value of UAldo of 12 μg/24h or greater was used to separate high and normal aldosterone.20,21PAC (reference range, 4.0 to 31.0 ng/dL; to convert to picomoles per liter, multiply by 27.74), PRA (reference range 1.31 to 3.95 ng·mL-1·h-1) and UAldo (reference range 2 to 16 μg/24h) were measured at commercial laboratories (Quest Diagnostics; Atlanta, GA, or Mayo Medical Laboratories, Rochester, MN) using standard techniques. The aldosterone to renin ratio (ARR) was calculated as PAC divided by PRA.OSA ScreeningAll subjects with resistant hypertension underwent full-night, attended, diagnostic polysomnography. Polysomnography evaluation included airflow monitoring with thermocouple and/or nasal pressure, respiratory effort using piezo belts at the chest and abdominal positions, oxygen saturation using pulse oximetry, heart rate using a 2-lead electrocardiogram, electroencephalogram (C4-A1, C3-A2, O2-A1, O1-A2), submental and tibial electromyograms, and bilateral electrooculograms. Apnea was defined as a cessation in airflow of at least 10 seconds. Hypopnea was defined as a reduction in the amplitude of airflow at least 30% for at least 10 second, followed by either a decrease in oxygen saturation of 4%, or signs of physiologic arousal (at least 3 s of α activity). The apnea-hypopnea index (AHI) was calculated as the total number of apneas plus hypopneas divided by the hours of sleep. Sleep was staged according to criteria of Rechtschaffen and Kales.22 The percentage of sleep time spent with an oxygen saturation less than 90%, the hypoxic index (HI), was also determined. Sleep stage and nocturnal events were scored by a registered polysomnographic technologist. The scoring of all studies was confirmed by an American Board of Sleep Medicine Diplomat blinded to the biochemical assessment. OSA was defined as an AHI of at least 5 per hour.22 Patients with significant central sleep apnea (> 5% of events) were excluded. No patient had Cheyne-Stokes respiration.Statistical EvaluationValues are reported as mean ± SD or median (range), where applicable. Variables were assessed for normality by Kolmogorov-Smirnov test. Values between groups were compared by t-test, Kruskal-Wallis (KW) test, χ2 test, or Fisher exact test, where appropriate. Correlation between AHI with PAC, UAldo, PRA, UNa, blood pressure, neck circumference, and body mass index (BMI) was evaluated by Pearson r or Spearman ρ correlation, where applicable. Two-tailed p values are provided for descriptive purposes, with p < 0.05 considered significant. Data analysis was carried out using JMP version 8.0 (SAS Institute Inc; Cary, NC).RESULTSPatient CharacteristicsIn total, 109 patients (50% men) with resistant hypertension were evaluated (Table 1). Thirty-one (28%) of the patients were classified as H-Aldo and 78 (72%) as N-Aldo. OSA was diagnosed in 84 (77%) patients: 26 (84%) of H-Aldo and 58 (74%) of N-Aldo patients. OSA and hyperaldosteronism were coexistent in 24% of study patients.Table 1 Demographic and biochemical values for all of the subjects and for subjects according to aldosterone statusParameterAll subjectsAldosterone levelTotal n = 109aHigh n = 31Normal n = 78 Men50.561.346.1 African American47.245.248.1 Age, y55.9 ± 9.156.4 ± 7.855.7 ± 9.7 BMI, kg/m233.3 ± 6.334.1 ± 5.533.0 ± 6.6 Neck, cm41.5 ± 4.342.0 ± 3.841.3 ± 4.5 Duration of HTN, y17.0 ± 10.218.3 ± 10.816.5 ± 10.0 Medicines, no.4.3 ± 1.04.3 ± 1.04.3 ± 1.0 Serum potassium, mmol/L3.9 ± 0.43.9 ± 0.43.9 ± 0.4 PAC, ng/dL11.9 ± 7.116.3 ± 8.110.2 ± 5.9b PRA, ng/mL/h2.4 ± 3.80.6 ± 0.13.1 ± 4.2b ARR14.4 ± 16.328.8 ± 21.28.6 ± 9.1b UAldo, μg/24h13.0 ± 9.019.1 ± 7.210.5 ± 8.5b UNa, mmol/24h186.2 ± 99.3200.5 ± 105.6180.7 ± 97.0 CrCl, mL/min116.0 ± 43.8127.0 ± 43.4111.7 ± 43.5 Data are shown as mean ± SD, except men and African American race, which are percentages. BMI refers to body mass index; HTN, hypertension; PAC, plasma aldosterone concentration; PRA, plasma renin activity; ARR, aldosterone renin ratio; UAldo, 24-hour urinary aldosterone excretion; UNa, 24-hour urinary sodium; Cr Cl, creatinine clearance.an = 109, except race, serum potassium, UNa (108); BMI (107); neck, CrCl (104), duration of HTN (101).bp < 0.0001 compared to High-Aldosterone group.Patients took an average of 4.3 ± 1.0 antihypertensive medications, which included a diuretic (91%), a β-receptor antagonist (76%), a calcium channel blocker (75%), an angiotensin-converting enzyme inhibitor (61%) or an angiotensin receptor blocker (58%), a α-receptor–blocking agent (9%), and other antihypertensive medications (42%). There were no significant differences in the number or type of prescribed antihypertensive medications between the H-Aldo and N-Aldo groups. There was no significant statistical difference in BMI, sex, age, and Cr Cl between the H-Aldo and N-Aldo groups. There were no statistically significant differences noted in diastolic blood pressure or heart rate (at any time measure) between the H-Aldo and N-Aldo groups. However, all systolic blood pressure measures including office and ambulatory blood pressure monitoring values (daytime, nighttime, and 24-h) were significantly higher in the H-Aldo compared with the N-Aldo group (p < 0.005).Relationship Between OSA and Aldosterone ConcentrationSeverity of OSA was greater in the H-Aldo versus The N-Aldo group. Median AHI and HI were significantly higher in the H-Aldo compared with the N-Aldo group (19.9 vs 10.0 events/h, KW p = 0.0491; and 7.0% vs 3.0%, KW p = 0.0041, respectively)(Table 2). Mean oxygen saturation (Mean O2) was lower in the H-Aldo compared with the N-Aldo group (93.2% vs 94.8%, KW p = 0.0185). PAC and UAldo were positively and significantly correlated with AHI in the H-Aldo group (Spearman ρ = 0.568, p = 0.0009; ρ = 0.533, p = 0.002, respectively). Although to a lesser degree, UAldo also correlated with AHI in the N-Aldo group (ρ = 0.224, p = 0.049). There was no significant correlation between PAC and AHI in the N-Aldo group (ρ = 0.015, p = 0.898) (Figure 1).Table 2 Polysomnography parameters for all subjects and for subjects according to aldosterone statusAll subjectsAldosterone StatusTotal n = 109High n = 31Normal n = 78Mean ± SDMedian (Range)Mean ± SDMedian (Range)Mean ± SDMedian (Range)AHI, events/h20.4 ± 21.711.5 (0.2-101.6)27.6 ± 26.219.9 (0.9-101.6)17.5 ± 19.0a10.0 (0.2-75.9)HI, %7.4 ± 11.13.3 (0.0-54.7)10.3 ± 12.17.0 (0.1-51.7)6.2 ± 10.6b3.0 (0.0-54.7)Mean SaO2, %94.6 ± 2.294.4 (89.6-99.8)93.8 ± 2.393.5 (89.6-99.3)95.0 ± 2.1c95.0 (89.6-99.8) SaO2 nadir, %79.8 ± 8.7782.1 (47.5-92.0)78.6 ± 10.182.9 (47.5-91.0)80.3 ± 8.281.8 (61.3-92.0) AHI refers to apnea-hypopnea index; HI, hypoxic index, defined as an SaO2 < 90%; SaO2, oxygen saturation.ap < 0.05 compared with the high-aldosterone group;bp < 0.01 compared with the high-aldosterone group;cp < 0.05 compared with the high-aldosterone group.Figure 1 Correlation between apnea-hypopnea index (AHI), plasma-aldosterone concentration (PAC), and 24-h urinary aldosterone excretion (UAldo) in high (H-Aldo) and normal (N-Aldo) aldosterone subjectsDownload FigureRelationship Among OSA, Aldosterone, and SexOSA was more common in male versus female patients (91% vs 63% respectively, p = 0.0005). Overall, men presented with significantly higher median AHI compared to women (20.3 vs 8.1 events/h, KW p < 0.0001). The sex difference in terms of severity of OSA was most pronounced in the H-Aldo subjects. In H-Aldo subjects, the median AHI was 29.8 in men versus 11.4 events/h in women (KW p = 0.0106), compared to 16.2 versus 6.9 events/h in the N-Aldo men versus women (KW p = 0.0018). An independent interaction between sex and OSA severity was tested for, but was not statistically present.DISCUSSIONPrevious studies from our center have noted an association among resistant hypertension, OSA, and aldosterone. In patients with resistant hypertension, aldosterone excretion is increased in patients with symptoms of OSA.19 We also have noted that PAC is significantly correlated with OSA severity.14 This current analysis extends these findings by determining the prevalence and severity of OSA according to aldosterone status in patients with resistant hypertension. OSA is extremely common in patients with resistant hypertension regardless of aldosterone status, but the severity is significantly worse in the H-Aldo patients. Furthermore, the severity of OSA is strongly correlated with the degree of aldosterone excess in the H-Aldo but not the N-Aldo patients.Inappropriate sodium and fluid retention characterize hyperaldosteronism, including in patients with resistant hypertension.7 Displacing fluid from the lower extremities to the neck results in upper airway narrowing, suggesting that upper airway edema may contribute importantly to the pathogenesis of OSA.23 A recent study of patients with diastolic heart failure, systemic hypertension, and OSA showed that diuretic treatment significantly improved upper airway caliber and OSA, further implicating pharyngeal edema as a cause of upper airway collapse during sleep.24 In addition, volumetric analysis techniques with magnetic resonance imaging demonstrate that the volume of the tongue and lateral walls independently increase risk of OSA.25 We hypothesize that intravascular fluid retention related to hyperaldosteronism and resultant pharyngeal edema contribute to the greater severity of OSA observed in patients with resistant hypertension and hyperaldosteronism. This hypothesis is supported by the findings of a recent study from our center showing that patients with resistant hypertension displayed evidence of intravascular volume expansion when compared with normotensive control subjects.17Impairment of ventilatory-control mechanisms also contribute to modulation of pharyngeal collapsibility during sleep.26 This suggests a role for central nervous system input, which may be influenced by humoral factors27 in addition to central and peripheral chemoreceptor activation.28–29 In animal models, aldosterone acts centrally to increase brain renin-angiotensin system activity, oxidative stress, and sympathetic drive.30 This aldosterone-induced activation of central receptors may result in dysregulation of normal central breathing mechanisms and potentially contribute to the association between excess aldosterone and severity of sleep apnea.OSA may lead to increased aldosterone release via stimulation of the renin-angiotensin system, as suggested by a previous study that demonstrated that blood pressure reduction following continuous positive airway pressure treatment correlated with reduction in PRA and angiotensin II levels.31 Furthermore, recent data suggest an interaction between angiotensin converting enzyme gene polymorphisms and OSA as a cause of hypertension.32 Thus, it is possible that OSA stimulates aldosterone secretion, which in turn leads to excess fluid retention, upper airway narrowing, and worsening of OSA. Such an occurrence could then result in a vicious cycle of OSA-induced aldosteronism and aldosterone-induced worsening of OSA. Confirmation of either or both components of this possible cycle requires further investigation.Strengths of the current study include its prospective design, large sample size, and assessment of OSA severity by attended fully diagnostic polysomnography. Potential limitations include the observational nature of the study and the fact that biochemical evaluation were conducted while patients were being maintained on their prescribed antihypertensive medication (except spironolactone, eplerenone, amiloride, or triamterene), although prior studies indicated that although some classes of agents predictably increase PRA (i.e., acetylcholine esterase inhibitor inhibitors, angiotensin receptor blockers, and diuretics), most do not significantly alter aldosterone levels.33,34In conclusion, we confirm that OSA is highly prevalent in patients with resistant hypertension and further characterize the emerging relationship among resistant hypertension, OSA, and aldosterone. In patients with resistant hypertension, the severity of OSA is greater in those patients with hyperaldosteronism and correlates with the degree of aldosterone excess. The findings of a high prevalence of OSA (77%), hyperaldosteronism (28%), and coexistent disease (24%) in patients with resistant hypertension emphasizes the clinical importance of considering the likelihood of patients presenting with resistant hypertension of having OSA, hyperaldosteronism, or both.PerspectivesThe positive relationship between hyperaldosteronism and severity of OSA observed in the current analysis supports the hypothesis that aldosterone excess contributes to the development of OSA. The results highlight the increased likelihood of hyperaldosteronism and OSA coexisting in patients with resistant hypertension and may explain, at least in part, the high prevalence of OSA in patients with resistant hypertension.DISCLOSURE STATEMENTThis was not an industry support study. The authors have indicated no financial conflicts of interest.ABBREVIATIONSACEangiotensin-converting enzymeAHIapnea-hypopnea indexARBangiotensin receptor blockerARRaldosterone to renin ratioBMIbody mass indexCPAPcontinuous positive airway pressureCr Clcreatinine clearanceH-Aldohigh-aldosterone statusHIhypoxic indexHTNhypertensionMean O2mean oxygen saturationN-Aldonormal-aldosterone statusOSAobstructive sleep apneaPACplasma aldosterone concentrationPRAplasma renin activityUAldo24-hour urinary aldosterone excretionUNa24-hour urinary sodiumREFERENCES1 Shamsuzzaman ASMGersh BJSomers VKObstructive sleep apnea. Implications for cardiac and vascular diseaseJAMA2003290190614, 14532320CrossrefGoogle Scholar2 Yaggi HKConcato JKernan WNLichtman JHBrass LMMohsenin VObstructive sleep apnea as risk factor for stroke and deathN Engl J Med2005353203441, 16282178CrossrefGoogle Scholar3 Shahar EWhitney CWRedline S, et al.Sleep-disordered breathing and cardiovascular diseaseAm J Respir Crit Care Med20011631925, 11208620CrossrefGoogle Scholar4 Young TFinn LPeppard PE, et al.Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep CohortSleep20083110718, 18714778Google Scholar5 Kuniyoshi FHSGarcia-Touchard AGami AS, et al.Day-night variation of acute myocardial infarction in obstructive sleep apneaJ Am Coll Cardiol2008523436, 18652941CrossrefGoogle Scholar6 Marin JMCarrizo SJVicente EAgusti AGNLon-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational studyLancet2005365104653, 15781100CrossrefGoogle Scholar7 Somers VKWhite DPAmin R, et al.American Heart Association Council for High Blood Pressure Research Professional Education CommitteeCouncil on Clinical CardiologyAmerican Heart Association Stroke CouncilAmerican Heart Association Council on Cardiovascular NursingAmerican College of Cardiology FoundationSleep Apnea and Cardiovascular Disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing CouncilCirculation20081181080111, 18725495Google Scholar8 Peppard PEYoung TPalta MSkatrud JProspective study of the association between sleep-disordered breathing and hypertensionN Engl J Med2000342137884, 10805822CrossrefGoogle Scholar9 Kales ABixler EOCadieux RJ, et al.Sleep apnea in hypertensive populationLancet1984210058, 6149395CrossrefGoogle Scholar10 Lavie PBen-Yosef RRubin AEPrevalence of sleep apnea syndrome among patients with essential hypertensionAm Heart J19841083736, 6464973CrossrefGoogle Scholar11 Williams AJHouston DFinberg SLam CKinney JLSantiago SSleep apnea syndrome and essential hypertensionAm J Cardiol198555101922, 3984861CrossrefGoogle Scholar12 Calhoun DAJones DTextor S, et al.Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure ResearchHypertension200851140319, 18391085CrossrefGoogle Scholar13 Logan AGPerlikowski SMMente A, et al.High prevalence of unrecognized sleep apnea in drug-resistant hypertensionJ Hypertens20011922717, 11725173CrossrefGoogle Scholar14 Pratt-Ubunama MNNishizaka MKBoedefeld RLCofield SSHarding SMCalhoun DAPlasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertensionChest20071314539, 17296647CrossrefGoogle Scholar15 Eide IKTorjesen PADrolsum ABabovic ALilledahl NPLow-renin status in therapy-resistant hypertension: a clue to efficient treatment J Hypertens200422221726, 15480108CrossrefGoogle Scholar16 Strauch BZelinka THampf MBernhardt RWidimsky JPrevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe regionJ Hum Hypertens20031734952, 12756408CrossrefGoogle Scholar17 Gaddam KKNishizaka MKPratt-Ubunama MN, et al.Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansionArch Intern Med2008168115964, 18541823CrossrefGoogle Scholar18 Calhoun DANishizaka MKZaman MAThakkar RBWeissmann PHyperaldosteronism among black and white subjects with resistant hypertensionHypertension2002408926, 12468575CrossrefGoogle Scholar19 Calhoun DANishizaka MKZaman MAHarding SMAldosterone excretion among subjects with resistant hypertension and symptoms of sleep apneaChest20041251127, 14718429CrossrefGoogle Scholar20 Mattsson CYoung WFPrimary aldosteronism: diagnostic and treatment strategiesNat Clin Pract Nephrol20062198208, 16932426CrossrefGoogle Scholar21 Funder JWCarey RMFardella C, et al.Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice GuidelineJ Clin Endocrinol Metab200893326681, 18552288CrossrefGoogle Scholar22 Rechtschaffen AKales AA manual of standardized terminology, techniques, and scoring system for sleep stages of human sleep1968Los AngelesBrain Information Service/ Brain Research Institute, UCLAGoogle Scholar23 Shiota SRyan CMChiu KL, et al.Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjectsThorax20076286872, 17442706CrossrefGoogle Scholar24 Bucca CBBrussino LBattisti A, et al.Diuretics in obstructive sleep apnea with diastolic heart failureChest20071324406, 17699130CrossrefGoogle Scholar25 Schwab RJPasirstein MPierson R, et al.Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imagingAm J Respir Crit Care Med200316852230, 12746251CrossrefGoogle Scholar26 Patil SPSchneider HSchwartz ARSmith PLAdult obstructive sleep apnea. Pathophysiology and diagnosisChest20071323257, 17625094CrossrefGoogle Scholar27 Wolk RJohnson BDSomers VKLeptin and the ventilatory response to exercise in heart failureJ Am Coll Cardiol20034216449, 14607453CrossrefGoogle Scholar28 Somers VKMark ALZavala DCAbboud FMInfluence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humansJ Appl Physiol1989672095100, 2513315CrossrefGoogle Scholar29 Somers VKMark ALZavala DCAbboud FMContrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humansJ Appl Physiol19896721016, 2513316CrossrefGoogle Scholar30 Zhang ZHYu YKang YMWei SGFelder RBAldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal ratsAm J Physiol Heart Circ Physiol2008294H106774, 18162560CrossrefGoogle Scholar31 Møller DSLind PStrunge BPedersen EBAbnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apneaAm J Hyperte" @default.
• W4294915483 created "2022-09-08" @default.
• W4294915483 creator A5002246155 @default.
• W4294915483 creator A5002269164 @default.
• W4294915483 creator A5016172583 @default.
• W4294915483 creator A5026714677 @default.
• W4294915483 creator A5034264304 @default.
• W4294915483 creator A5041227703 @default.
• W4294915483 creator A5043389439 @default.
• W4294915483 creator A5060254061 @default.
• W4294915483 creator A5071337091 @default.
• W4294915483 date "2010-08-15" @default.
• W4294915483 modified "2023-10-03" @default.
• W4294915483 title "Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension" @default.
• W4294915483 doi "https://doi.org/10.5664/jcsm.27878" @default.
• W4294915483 hasPublicationYear "2010" @default.
• W4294915483 type Work @default.
• W4294915483 citedByCount "111" @default.
• W4294915483 countsByYear W42949154832012 @default.
• W4294915483 countsByYear W42949154832013 @default.
• W4294915483 countsByYear W42949154832014 @default.
• W4294915483 countsByYear W42949154832015 @default.
• W4294915483 countsByYear W42949154832016 @default.
• W4294915483 countsByYear W42949154832017 @default.
• W4294915483 countsByYear W42949154832018 @default.
• W4294915483 countsByYear W42949154832019 @default.
• W4294915483 countsByYear W42949154832020 @default.
• W4294915483 countsByYear W42949154832021 @default.
• W4294915483 countsByYear W42949154832022 @default.
• W4294915483 countsByYear W42949154832023 @default.
• W4294915483 crossrefType "journal-article" @default.
• W4294915483 hasAuthorship W4294915483A5002246155 @default.
• W4294915483 hasAuthorship W4294915483A5002269164 @default.
• W4294915483 hasAuthorship W4294915483A5016172583 @default.
• W4294915483 hasAuthorship W4294915483A5026714677 @default.
• W4294915483 hasAuthorship W4294915483A5034264304 @default.
• W4294915483 hasAuthorship W4294915483A5041227703 @default.
• W4294915483 hasAuthorship W4294915483A5043389439 @default.
• W4294915483 hasAuthorship W4294915483A5060254061 @default.
• W4294915483 hasAuthorship W4294915483A5071337091 @default.
• W4294915483 hasBestOaLocation W42949154831 @default.
• W4294915483 hasConcept C111919701 @default.
• W4294915483 hasConcept C126322002 @default.
• W4294915483 hasConcept C164705383 @default.
• W4294915483 hasConcept C2775841894 @default.
• W4294915483 hasConcept C2776006263 @default.
• W4294915483 hasConcept C2777935920 @default.
• W4294915483 hasConcept C2778525890 @default.
• W4294915483 hasConcept C3019558611 @default.
• W4294915483 hasConcept C41008148 @default.
• W4294915483 hasConcept C71924100 @default.
• W4294915483 hasConcept C84393581 @default.
• W4294915483 hasConceptScore W4294915483C111919701 @default.
• W4294915483 hasConceptScore W4294915483C126322002 @default.
• W4294915483 hasConceptScore W4294915483C164705383 @default.
• W4294915483 hasConceptScore W4294915483C2775841894 @default.
• W4294915483 hasConceptScore W4294915483C2776006263 @default.
• W4294915483 hasConceptScore W4294915483C2777935920 @default.
• W4294915483 hasConceptScore W4294915483C2778525890 @default.
• W4294915483 hasConceptScore W4294915483C3019558611 @default.
• W4294915483 hasConceptScore W4294915483C41008148 @default.
• W4294915483 hasConceptScore W4294915483C71924100 @default.
• W4294915483 hasConceptScore W4294915483C84393581 @default.
• W4294915483 hasIssue "04" @default.
• W4294915483 hasLocation W42949154831 @default.
• W4294915483 hasOpenAccess W4294915483 @default.
• W4294915483 hasPrimaryLocation W42949154831 @default.
• W4294915483 hasRelatedWork W1995527129 @default.
• W4294915483 hasRelatedWork W2063653080 @default.
• W4294915483 hasRelatedWork W2082981388 @default.
• W4294915483 hasRelatedWork W2085796976 @default.
• W4294915483 hasRelatedWork W2089884582 @default.
• W4294915483 hasRelatedWork W2883899157 @default.
• W4294915483 hasRelatedWork W2944985375 @default.
• W4294915483 hasRelatedWork W3036540864 @default.
• W4294915483 hasRelatedWork W4230944459 @default.
• W4294915483 hasRelatedWork W4295775062 @default.
• W4294915483 hasVolume "06" @default.
• W4294915483 isParatext "false" @default.
• W4294915483 isRetracted "false" @default.
• W4294915483 workType "article" @default.